Publications Repository

Publications Repository

Search 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • Search
  • Home
  • ICR Divisions
  • Clinical Studies
  • Search
JavaScript is disabled for your browser. Some features of this site may not work without it.

Search

Show advanced filtersHide advanced filters

Filters

Use filters to refine the search results.

Now showing items 1-10 of 178

  • Sort Options:
  • Relevance
  • Issue date (newest)
  • Issue date (oldest)
  • Results Per Page:
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
Thumbnail

Health-related quality of life results from the phase III CheckMate 067 study. 

Schadendorf, D; Larkin, J; Wolchok, J; Hodi, FS; Chiarion-Sileni, V; et al. (2017-09)
Background Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as ...
Thumbnail

Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. 

Tokaca, N; Wotherspoon, A; Nicholson, AG; Fotiadis, N; Thompson, L; et al. (2017-09)
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed ...
Thumbnail

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. 

D'Angelo, SP; Larkin, J; Sosman, JA; Lebbé, C; Brady, B; et al. (2017-01)
Purpose Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a ...
Thumbnail

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. 

Bowyer, S; Prithviraj, P; Lorigan, P; Larkin, J; McArthur, G; et al. (2017-04)
Thumbnail

Emergency Presentation of Esophagogastric Cancer: Predictors and Long-term Prognosis. 

Markar, SR; Mackenzie, H; Jemal, S; Faiz, O; Cunningham, D; et al. (2018-04)
Objective To identify patient factors that are associated with emergency presentation of esophageal and gastric cancer, and further to evaluate long-term prognosis in this cohort.Background The incidence of emergency ...
Thumbnail

The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. 

Noujaim, J; Jones, RL; Swansbury, J; Gonzalez, D; Benson, C; et al. (2017-02)
Background EWSR1 rearrangements were first identified in Ewing sarcoma, but the spectrum of EWSR1-rearranged neoplasms now includes many soft tissue tumour subtypes including desmoplastic small round cell tumour (DSRCT), ...
Thumbnail

Treatment of retroperitoneal sarcoma: current standards and new developments. 

van Houdt, WJ; Zaidi, S; Messiou, C; Thway, K; Strauss, DC; et al. (2017-07)
Purpose of review Retroperitoneal sarcomas are rare tumors and with complex treatment. In this manuscript we give an overview of current standards in treatment of this disease and discuss new developments.Recent findings ...
Thumbnail

Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. 

Smyth, E; Zhang, S; Cunningham, D; Wotherspoon, A; Soong, R; et al. (2017-12)
Purpose: Germline polymorphisms may affect chemotherapy efficacy and toxicity. We examined the effect of polymorphisms in drug metabolism and DNA repair genes on pathologic response rates, survival, and toxicity for patients ...
Thumbnail

Circulating tumor DNA-From bench to bedside. 

Lim, JSJ; Janku, F; Yap, TA (2017-05)
In the era of personalized medicine, tumor sampling is paramount to enable the assessment of actionable molecular aberrations to help rationalize and guide treatment decisions. Longitudinal tracking of such aberrations may ...
Thumbnail

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. 

Helgadottir, H; Kis, L; Ljungman, P; Larkin, J; Kefford, R; et al. (2017-07)
  • «
  • 1
  • 2
  • 3
  • 4
  • . . .
  • 18
  • »

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types

Discover

Author
Marsden, (178)
Cunningham, David (38)Larkin, James (36)Jones, Robin (27)Popat, Sanjay (20)... View MoreSubjectHumans (154)Female (89)Middle Aged (77)Male (73)Aged (70)... View MoreDate Issued2018 (15)2017 (162)Publication TypeJournal Article (173)Other (5)
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.